# InofabHealth

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/inofabhealth

- Industry: Medical Devices & Equipment
- Headquarters: Ankara, Turkey
- Website: www.inofab.health
- Total disclosed funding: $1.5M
- Latest round: Seed (May 31, 2018)
- Investors on record: 3

## About

InofabHealth, based in Turkey, specializes in innovative respiratory health solutions, providing advanced spirometry devices for home and clinical use, facilitating effective lung function monitoring and management for diverse users.InofabHealth focuses on developing respiratory health products, including the SpiroHome and SpiroClinic Pro. Founded in 2014 in Ankara, Turkey, by Kerem Yasar and Merthan Öztürk, the company has engaged in 6 deals to date, with the most recent funding round being a Series A in November 2023, raising USD 1.000 mn from Fark Labs, Technology Development Foundation of Turkey, and re-pie. InofabHealth was acquired by Clario in November 2023, marking a shift in its strategic direction.InofabHealth specializes in advanced respiratory health solutions, primarily through its flagship products, the SpiroHome personal ultrasonic spirometer and the SpiroClinic Pro spirometry platform. The SpiroHome device enables users to conduct lung function tests in the comfort of their homes, allowing individuals to monitor their lung health trends via the SpiroHome mobile app. The SpiroClinic Pro, designed for clinical environments, integrates with hospital electronic health records and enhances the efficiency of lung function testing through state-of-the-art ultrasonic technology. These products aim to address the growing need for accessible respiratory health management, benefiting both individual users and healthcare facilities. Their client base includes hospitals, clinics, research centers, and private individuals, with their products marketed primarily in North America, Europe, and select regions in Asia.InofabHealth's revenue model is structured around the sale of its medical devices and subscription services associated with the SpiroCloud web dashboard. Clients, including healthcare providers and institutions, can purchase the SpiroHome and SpiroClinic Pro products, which often come with the option for additional smart accessories to enhance user experience and adherence to treatment protocols. Transaction modalities could encompass direct-to-consumer sales for personal spirometers and B2B agreements for bulk purchases by clinics and hospitals. The company may offer various pricing plans, though specific costs for products and services are incorporated into the overall transaction framework. The combination of device sales and ongoing software support aims to generate a sustainable revenue stream as the demand for digital respiratory care solutions continues to expand.InofabHealth plans to leverage its recent acquisition by Clario to expand its product offerings and market reach. The company is focusing on developing new respiratory health technologies and aims to introduce additional products by the end of 2024. They are also targeting expansion into new markets, particularly in Asia and Europe, by early 2025, utilizing funds from their latest Series A round to support these initiatives and enhance their operational capabilities.

## Funding rounds

- Seed, May 31, 2018, $1.3M — ACT Venture Partners, Growth Circuit Ventures
- Seed, May 4, 2017, $0.2M — 500 Global, ACT Venture Partners

## Investors

- 500 Global (https://capitalatlas.ai/funds/500-global) — Seed
- ACT Venture Partners (https://capitalatlas.ai/funds/act-venture-partners) — Seed
- Growth Circuit Ventures (https://capitalatlas.ai/funds/growth-circuit-ventures) — Seed